Pacgen Life Science Corporation acquired by Taiwan-based pharma company
Date Closed
September 30, 2020
Lead Office
Vancouver
Value
1.78 Million CAD
On September 30, 2020, Pacgen Life Science Corporation (Pacgen) was acquired by General Biologicals Corporation (GBC), a Taiwan-based diagnostic and pharmaceutical company. The transaction took place by way of a court-approved plan of arrangement, through which GBC acquired all outstanding shares of Pacgen in an all cash transaction.
The implied equity value of the plan of arrangement is C$1.782 million.
Pacgen is a life sciences company that sells and markets over sixty different products in oral care, skin care and health supplement segments.
McCarthy Tétrault advised Pacgen with a team led by Robin Mahood that included Miranda Lam, Xinya Wang, Alyssa Leung and Firuz Rahimi (M&A), Vincent Yip (Intellectual Property), and Jeremy Ho (Tax).
